Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Sandoz to license three biosimilar drugs from Shanghai Henlius Biotech

17 August 2026 · By · Wire by Fusion42

Published

17 August 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

China

◆ Source

Read at srnnews.com →

◆ Verified

Fusion42 · 17 August 2026 · Fusion42 review

Sandoz has entered a licensing agreement to acquire three biosimilar drugs from Shanghai Henlius Biotech, expanding its biosimilar portfolio and access to the Chinese biopharmaceutical innovation.

This Wire brief sits within Fusion42's coverage of Biotech, and 3 sources have reported it.

◆ ◆ The Wire takeaway

You now have a fresh route to enter or expand in the Chinese biosimilar market via Sandoz's licensed portfolio. Act this week to assess partnership or competitive threats from Henlius innovations reaching global markets.

◆ Coverage

3 sources · 17 Aug 2026

◆ Related on Wire

◆ Topics

Biotechbiosimilarslicensingbiotechchinapharma